Subcutaneous VELCADE Approved in the EU for the Treatment of Multiple Myeloma (Part 2 of 2)

tvnportal
1.3K
39 views
  • About
  • Export
  • Add to
Janssen-Cilag International NV (Janssen) today announced that the European Commission has granted marketing authorisation for the subcutaneous (under the skin) administration of VELCADE (bortezomib) in the European Union. Bortezomib is indicated for the treatment of multiple myeloma, a type of blood cancer.1 The authorisation is based on data from a Phase III study demonstrating that subcutaneous administration of bortezomib is equally effective as intravenous
Powered by NewsLook.com
Producer : Business Wire

0 comments